Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibritumomab tiuxetan - Acrotech Biopharma /Biogen

X
Drug Profile

Ibritumomab tiuxetan - Acrotech Biopharma /Biogen

Alternative Names: 111In-ibritumomab tiuxetan; BAY86-5128; IDEC-129; IDEC-In2B8; IDEC-Y2B8; Indium-111 Ibritumomab tiuxetan; Monoclonal antibody IDEC-Y2B8; SH-L-749; Yttrium-90 ibritumomab tiuxetan; ZEVALIN; Zevalin; Zevamab

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Acrotech Biopharma; Bayer Yakuhin; Biogen; CASI Pharmaceuticals; Dana-Farber Cancer Institute; Schering Korea; Tufts-New England Medical Center
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma
  • Discontinued Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma

Most Recent Events

  • 16 Mar 2020 CASI Pharmaceuticals plans registration trial for Non-Hodgkin's lymphoma in China in early 2021
  • 06 Mar 2019 Spectrum Pharmaceuticals completes sale of ibritumomab tiuxetan to Acrotech Biopharma
  • 19 Feb 2019 The National Medical Products Administration (NMPA) of China approves a clinical trial application for the conduction of a confirmatory clinical trial of ibritumomab tiuxetan in Non-Hodgkin's lymphoma (Second-line therapy or greater)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top